← FDA DRUG APPROVALS

FDA ANDA · ANDA090581

AMPICILLIN SODIUM

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA090581
TYPE
ANDA
ORIGINAL APPROVAL
2015-10-20
LATEST ACTION
2024-05-01
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 10GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-05-01Labeling · Supplement 5 · standardAP
2019-11-18Labeling · Supplement 3 · standardAP
2018-02-15Labeling · Supplement 2 · standardAP
2015-10-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →